Adesh Kaul - Basilea Pharmaceutica Chief Officer
| BSLN Stock | CHF 42.10 0.80 1.94% |
Insider
Adesh Kaul is Chief Officer of Basilea Pharmaceutica AG
| Age | 49 |
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christian Wichert | Evolva Holding SA | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Oliver Strub | Santhera Pharmaceuticals Holdin | 60 | |
| Julien LLM | Idorsia | 44 | |
| Michael Stumpp | Molecular Partners AG | 51 | |
| Luigi Longo | COSMO Pharmaceuticals SA | 44 | |
| Sarah HolmesKlotz | Santhera Pharmaceuticals Holdin | N/A | |
| Marco Lecchi | COSMO Pharmaceuticals SA | 59 | |
| Fabienne Gschwind | Evolva Holding SA | 50 | |
| Mauro Ajani | COSMO Pharmaceuticals SA | 68 | |
| Shabir MD | Santhera Pharmaceuticals Holdin | N/A | |
| Alexander Zurcher | Molecular Partners AG | N/A | |
| Renate Gloggner | Molecular Partners AG | N/A | |
| Ngo Nhan | COSMO Pharmaceuticals SA | 44 | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Kaspar Mueller | Evolva Holding SA | 60 | |
| Davide Malavasi | COSMO Pharmaceuticals SA | 50 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Andrew Weiss | Idorsia | 55 | |
| Andreas EMBA | Molecular Partners AG | 57 | |
| Neville MD | Santhera Pharmaceuticals Holdin | N/A | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lutz Wevelsiep, Head Affairs | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| David Veitch, Chief Officer | ||
| Ursula Eberhardt, Head HR | ||
| Marc MD, Chief Officer | ||
| Peer Schroder, Head Relations | ||
| Dietrich Stber, Head Services | ||
| Laurenz Kellenberger, Chief Officer |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 670.47 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.05 % | |||
| Shares Owned By Institutions | 28.93 % | |||
| Price To Earning | 190.88 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 148.12 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.